Novo Holdings has co-led with Vivo Capital the over-subscribed USD200 million Series A and Crossover round in Esco Lifesciences Group (Esco), a leading provider of life sciences tools and services.

The financing will enable Esco to strengthen its position through organic and external growth and transformation, as well as invest in China, thus addressing some of the most dynamic market segments and geographies. Other investors include two Asian sovereign wealth funds and Singapore-based global investor, EDBI.

Esco is a world-leading manufacturer of laboratory and biopharma equipment and IVF medical devices, with four divisions, namely, Scientific, Medical, Healthcare, and Aster, which offers mission-critical equipment and advanced solutions to a broad diversity of laboratories, clinics and bio-pharma production sites in over 100 countries, thus contributing to the future of life science research and manufacturing.

Read more at Private Equity Wire